NDA 219016 · Janssen Prods
Edurant Ped
Rilpivirine Hydrochloride · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Mar 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Mar 15, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
146
54 Phase 3, 10 recruiting
FAERS reports
55
52 serious, 6 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 28, 2025.
EDURANT and EDURANT PED are a human immunodeficiency virus type 1 (HIV-1) specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve patients 2 years of age and older and weighing at least 14 kg with HIV-1 RNA less than or equal to 100,000 copies/mL. ( 1.1 ). Limitations of Use: More EDURANT treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA ≥50 copies/mL) compared to EDURANT treated subjects with HIV-1 RNA less than or equal to 100,000 copies/mL. ( 1.1 , 14 ) EDURANT is indicated in combination with VOCABRIA (cabotegravir), for short-term treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine. ( 1.2 ) 1.1 Treatment of HIV-1 in Treatment-Naïve Patients EDURANT and EDURANT PED, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients 2 years of age and older and weighing at least 14 kg with plasma HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy. Limitations of Use More EDURANT treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA ≥50 copies/mL) compared to EDURANT treated subjects with HIV-1 RNA less than or equal to 100,000 copies/mL [see Clinical Studies (14.1) ] . 1.2 Treatment of HIV-1 in Combination with...
Mechanism: Rilpivirine is an antiviral drug [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EDURANT PED · RILPIVIRINE HYDROCHLORIDE EQ 2.5MG BASE · TABLET, FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rilpivirine" as an intervention, any sponsor and status, largest first.
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum WomenPivotal-lookingCompleted
International Maternal Pediatric Adolescent AIDS Clinical Trials GroupResearch network
NCT00955968 · 1,653 participants · Start Jan 1, 2010 · Primary completion Aug 31, 2016
Drug: Highly active antiretroviral therapy (HAART) · For: HIV Infection
Sites: Alhambra, California; Los Angeles, California; San Diego, California · 50 sites in all
- RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled InfectionPivotal-lookingStatus unknown
A.O. Ospedale Papa Giovanni XXIIIAcademic, hospital or other
NCT04064632 · 1,609 participants · Start Feb 1, 2017 · Primary completion Jun 13, 2019
Drug: Rilpivirine + darunavir/cobicistat · For: HIV Infection
Sites: Bergamo, Italy
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT03299049 · 1,049 participants · Start Oct 27, 2017 · Primary completion Jun 6, 2019
Drug: Cabotegravir Tablets; Rilpivirine Tablets and 2 more · For: HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 119 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02345226 · 881 participants · Start Jan 26, 2015 · Primary completion Jun 29, 2016
Drug: FTC/RPV/TAF; EFV/FTC/TDF Placebo and 2 more · For: HIV-1 Infection
Sites: Phoenix, Arizona; Beverly Hills, California; Long Beach, California · 117 sites in all
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07682961 · 850 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 4 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Hidden Valley Lake, California · 61 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT01309243 · 799 participants · Start Feb 2011 · Primary completion Sep 2012
Drug: FTC/RPV/TDF; EFV/FTC/TDF · For: HIV-1 Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Beverly Hills, California · 151 sites in all
- Kuwa Free! - Live Free!Pivotal-lookingRecruiting
University of Alabama at BirminghamAcademic, hospital or other
NCT05044962 · 700 participants (planned) · Start Nov 26, 2021 · Primary completion Mar 31, 2027
Drug: Cabotegravir/ Rilpivirine; Etonogestrel (ETG) implant and 3 more · For: HIV Infections; Contraception; Drug-drug Interaction
Sites: Eldoret, Kenya
- TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.Pivotal-lookingCompleted
Tibotec Pharmaceuticals, IrelandIndustry
NCT00540449 · 694 participants · Start May 2008 · Primary completion Feb 2010
Drug: TMC278; Efavirenz · For: HIV Infections; HIV-1; Human Immunodeficiency Virus Type 1
Sites: Birmingham, Alabama; Phoenix, Arizona; Beverly Hills, California · 92 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- depressed mood4
- drug interaction4
- insomnia4
- off label use4
- rash4
- abnormal dreams3
- acute kidney injury3
- confusional state3
- depression3
- disorientation3
- fatigue3
- haemoglobin decreased3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 8 |
| 2019 | 9 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W, Zhao S, Wu Y, et al. · JMIR Public Health Surveill 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Long-Acting HIV Therapy in African Adults with Adherence Challenges.
Cresswell FV, Kitonsa J, Norcross C, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, et al. · Lancet HIV 2023 · Randomized Controlled Trial, Multicenter Study
- Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Naggie S, Cooper C, Saag M, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.